Correspondence Regarding Lee et al.: Placebo Control is Vital in Assessing Therapy in Chronic Cough.

A letter published in the journal Lung discusses a study on the efficacy of high-dose inhaled corticosteroid (ICS) therapy in adults with chronic cough. The study found that patient-reported outcomes significantly improved and fractional exhaled nitric oxide (FeNO) levels declined after three weeks of ICS therapy. However, the letter argues that the study's lack of a placebo control introduces bias and suggests that the reported improvement may be due to a placebo response rather than a pharmacological mechanism. The authors disagree with the guideline recommendation for a short-term ICS trial for chronic cough and propose alternative approaches for diagnosis and treatment. [Extracted from the article]

Copyright of Lung is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)